⚠️
od kwietnia 2026 zmiany w katalogu chemioterapii: radykalna i paliatywna CTH gruczolakoraka przełyku → docetaksel; 1. L zaawansowanego raka żółądka → paklitaksel
Terapie w programie lekowym:
Leki w katalogu chemioterapii:
Bleomycin Sulphate
Capecitabine
Capecitabine (2)
Carboplatin
Cisplatinum
Cyklophosphamidum
Dacarbazinum
Denosumab
Docetaxel
Docetaxelum
Doxorubicinum
Epirubicinum
Etoposidum
Fluorouracilum
Ifosfamidum
Imatinibum
Irinotecanum
Lanreotidum
Octreotidum
Oxaliplatinum
Oxaliplatinum (2)
Paclitaxel
Sorafenib
Sunitinib
Temozolomidum
Trastuzumabum I.v.
Vincristinum
Vinorelbinum
Badania kliniczne w Polsce - zobacz więcej w 🔍 wyszukiwarce
- gastric cancer
- esophageal cancer
- » A Randomized, Multicenter Clinical Trial Comparing the Combination of Perioperative FLOT Chemotherapy and Preoperative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Plus Gastrectomy to Perioperative FLOT Chemotherapy and Gastrectomy Alone in Patients With Advanced Gastric Cancer at High Risk of Peritoneal Recurrence
- » A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
- » Stereotactic Body Radiotherapy in Addition to Standard of Care Treatment in Patients With Rare Oligometastatic Cancers (OligoRARE): a Randomized, Phase 3, Open-label Trial
- » Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults
- » A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies